Superluminal Medicines – Talk Bio

Actionable Insights Powered by AI

Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases

4 weeks ago talkbio0Tagged Aortic Valve Insufficiency, cardiometabolic diseases, Eli, Eli Lilly, equity, GPCRs, Investments, MC4R, MC4R protein, human, milestones, Obesity, Partnership, Superluminal Medicines

Eli Lilly; Superluminal Medicines; GPCRs; obesity drugs; cardiometabolic diseases; AI drug discovery; MC4R; partnership; milestones; equity investment

Superluminal Medicines Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials

1 year ago talkbio0Tagged AI-focused, Clinical Trials, Eli, Eli Lilly, Funding, Investments, Membrane receptor, Series, Superluminal Medicines

Superluminal Medicines, Series A funding, membrane receptor drugs, clinical trials, AI-focused biotech, Eli Lilly investment